MedDataX Logo

Imagery Rescripting in the Treatment of Post Traumatic Stress Disorder (PTSD) Following Early Chronic Interpersonal Trauma

NCT ID: NCT01464892

Last Updated: 2021-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Imagery Rescripting (IR)is a promising treatment for PTSD in adult survivors of early, chronic, interpersonal trauma (e.g. Smucker \& Dancu, 1999). So far, this protocol has not been investigated within a controlled setting with patients with PTSD following early, chronic, interpersonal trauma. The aim of the proposed study is to 1. investigate the efficacy of Imagery Rescripting and 2. check whether the efficacy of Imagery Rescripting can be improved by adding a stabilization phase (Skills training in affective and interpersonal regulation, STAIR) prior to this treatment. In a randomized controlled trial three conditions will be compared:

1. Imagery Rescripting
2. STAIR + Imagery Rescripting
3. Wait-list control

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Posttraumatic Stress Disorder (PTSD)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Imagery rescripting Imagery rescripting and reprocessing therapy Skills Training in affective and interpersonal regulation Post-traumatic Stress Disorder Childhood abuse Childhood sexual abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Imagery Rescripting

Group Type EXPERIMENTAL

Imagery Rescripting and Reprocessing Therapy

Intervention Type BEHAVIORAL

This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting

STAIR plus Imagery Rescripting

Group Type ACTIVE_COMPARATOR

STAIR + Imagery Rescripting

Intervention Type BEHAVIORAL

A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.

Wait-list control

Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imagery Rescripting and Reprocessing Therapy

This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting

Intervention Type BEHAVIORAL

STAIR + Imagery Rescripting

A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IRRT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a full diagnosis of post-traumatic stress disorder (PTSD) according to DSM-IV
* having experienced repeated or chronic interpersonal trauma by care-takers or authority figures before the age of 15
* between the age of 18 and 65 years
* sufficient fluency of Dutch to complete treatment and research-protocol
* participants using prescribed anti-depressant medication are required to be on a stable dose for at least 6 weeks before the beginning of treatment and remain on this dose throughout the treatment

Exclusion Criteria

* psychosis
* bipolar disorder
* significant cognitive impairment
* substance dependence
* current use of benzodiazepines
* severe suicidal ideation or life-threatening automutilation
* current trauma or threat
* unstable living circumstances
* antisocial personality disorder
* primary diagnosis of borderline personality disorder
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Amsterdam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mrs. M. Kindt

Professor of Experimental and Clinical Psychology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Merel Kindt, Prof dr

Role: PRINCIPAL_INVESTIGATOR

University of Amsterdam

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Amsterdam

Amsterdam, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-KP-877

Identifier Type: -

Identifier Source: org_study_id